Clinical

Increasing at-home access to care and treatment options for spinal muscular atrophy (SMA) proved to be helpful during the coronavirus disease 2019 (COVID-19) pandemic, explained Mary Schroth, MD, FAAP, FCCP, chief medical officer at Cure SMA.

The study of over 8000 patients with myeloproliferative neoplasms (MPNs) also found that these patients were 40% more likely to have a prior diagnosis of inflammatory bowel disease (IBD).

A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.

Differences in long-term outcomes in patients with rheumatoid arthritis (RA) may because RA with and without autoantibodies are actually 2 distinct conditions.

Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

Efficacy and safety of atezolizumab as first-line therapy for metastatic non–small cell lung cancer (NSCLC) with high levels of PD-L1 expression is not known, the authors said.

The majority of patients with asthma have type 2 inflammation, and the introduction of dupilumab has changed the treatment space for these patients, said Neal Jain, MD, FAAP, FAAAAI.

Study results presented during the virtual European Society for Medical Oncology meeting demonstrated the superiority of cemiplimab (Libtayo) plus ipilimumab vs cemiplimab monotherapy for non–small cell lung cancer.

A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.

Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.

The study is part of Moderna’s larger trial to find a vaccine to prevent coronavirus disease 2019, which puts older adults, who have weaker immune responses, at a higher risk of more severe illness and death.

Researchers assess the optimal balance of levodopa in patients with Parkinson disease (PD), which wanes in efficacy as PD progresses and can contribute to uncontrollable, involuntary bodily movements if given in too high of a dosage.

Tailoring treatment to individual patients is the ultimate goal in the complex decision-making process of managing progressive multiple sclerosis (MS), noted Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, Mayo Clinic.

A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.

There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.

A study looking at older adults with chronic pain found no significant difference in cognitive performance when comparing them with matched patients who did not use medical cannabis.

Researchers hope that a more targeted retinoid acid X receptor compound could repair myelin without the adverse effects seen in every patient in this trial, which tested an already approved cancer drug.

Over 12.5 years of follow-up, close to 10% of participants developed incident heart failure in a recent study that investigated possible differentiation of cardiovascular (CV) risk factors and biomarkers based on sex.

Patients with migraine who took lasmiditan (Reyvow) for acute pain during attacks had greater odds of reaching pain freedom, according to results of a phase 3 trial.

Higher body mass index based on genes is associated with a risk of developing rheumatoid arthritis, according to an analysis of genetic data published in Arthritis & Rheumatology.

The results were shared as part of the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, which is concluding Saturday with a special session about coronavirus disease 2019 (COVID-19).

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.

Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.

Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for non–small cell lung cancer (NSCLC).

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

Relapse at an older age can significantly contribute to a worsening of multiple sclerosis (MS), explained Burcu Zeyda, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100.

FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.

The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC.

A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.